ArticleHaematologica2024

LILRB4 represents a promising target for immunotherapy by dual targeting tumor cells and myeloid-derived suppressive cells in multiple myeloma.

Lixin Gong et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.